The recent CorMicA (Coronary Microvascular Angina) trial revealed that patients may benefit when coronary microvascular dysfunction (CMD) is accurately diagnosed and appropriately treated.1 Learn more about diagnosing and treating CMD.
RFR clinical evidence derives from assessing over 3,500 lesions in 2,000 patients, and much of that evidence is from ILUMIEN I + PREDICT, VALIDATE RFR, IRIS-FFR and RE-VALIDATE RFR.2-6
Fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) is supported by more than 600 published studies including the FAME clinical trials.7-9
When integrated into cardiac cath lab procedures, measurement of FFR has been shown to reduce the incidence of major adverse coronary events (MACE) in patients being treated for complex coronary artery disease.
The FAME study—evaluating complex lesions—examined FFR measured exclusively by the PressureWire™ Certus System. Results showed that compared to angiography alone, FFR:
Precise measurement of intravascular diagnostics relies on the market-leading PressureWire™ X Guidewire that combines excellent maneuverability—even in tortuous vessels—and reliable readings11, all of which can ensure accurate information in the cath lab.
You are about to enter an Abbott country- or region-specific website.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions
Do you wish to continue and enter this website?